【百奥泰:BAT2206(乌司奴单抗)注射液上市许可申请获得受理】财联社5月8日电,百奥泰公告,BAT2206(乌司奴单抗)注射液上市许可申请获得受理。
“特别声明:以上作品内容(包括在内的视频、图片或音频)为凤凰网旗下自媒体平台“大风号”用户上传并发布,本平台仅提供信息存储空间服务。
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services.”